Navigation Links
Former NxStage System One User Celebrates One-Year Kidney Transplant Anniversary
Date:8/29/2011

LAWRENCE, Mass., Aug. 29, 2011 /PRNewswire/ -- NxStage® Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that former NxStage® System One™ patient Tederra Coleman is celebrating the one-year anniversary of her successful kidney transplant. Coleman, 33, of Pompano Beach, Florida, received her transplant after experiencing two years of daily home hemodialysis with the NxStage System One™. Prior to beginning daily home hemodialysis, Coleman spent seven years undergoing thrice-weekly treatments at a dialysis center.

(Logo:  http://photos.prnewswire.com/prnh/20110503/MM94799LOGO)

More frequent dialysis with the System One resulted in such a positive change in Coleman's health and quality of life, that she became a certified hemodialysis technician. Her goal is to inform patients about their therapy options, including home hemodialysis with the System One so they can experience the benefits possible with this life changing therapy.  

"As an in-center dialysis patient, I didn't like going to the center and the strict schedule was difficult to keep with my job, so I often skipped my treatments, putting my health in jeopardy," said Coleman. "It was my desire to dialyze at home that motivated me to become a compliant patient. Once I began using the System One, I finally felt in control of my life and health and managed my dialysis care properly, which allowed me to become a transplant candidate."

"Recent objective clinical data from large, well designed trials have proven that more frequent hemodialysis with the System One has a positive impact on patient survival, clinical outcomes and quality of life," stated Jeffrey H. Burbank, Chief Executive Officer of NxStage Medical. "We're pleased to celebrate with Tederra and other patients for whom more frequent hemodialysis with the System One not only allows them to live better, healthier lives, but also may better position them for transplant success."

The Tederra Coleman Story

Tederra Coleman was diagnosed with end stage renal disease (ESRD) at the age of 24 upon a visit to her doctor for a regular checkup.  Tederra's demanding in-center dialysis schedule eventually forced her to quit her job as a customer service representative.

Coleman learned of NxStage's portable home hemodialysis machine, the System One, in 2008. After completing training with her daughter and trained partner, Ternisha, Coleman began dialyzing at her home five times a week for two hours at a time. The pair typically conducted Tederra's treatments after Ternisha finished her homework. During her time on the System One therapy, Tederra noticed a marked improvement in her energy levels and mental wellbeing.

Tederra had been placed on the kidney transplant list after beginning therapy with the System One. Two years later, in August of 2010, Tederra received a successful kidney transplant.

Today, Tederra is a certified hemodialysis technician. Inspired and intrigued with her mother's therapy, Tederra's daughter, Ternisha, wishes to pursue a career in healthcare and will begin classes this fall at Florida State University College of Medicine.

About the NxStage System One

The NxStage System One is the first and only truly portable hemodialysis system cleared for home use by the U.S. Food & Drug Administration (FDA). Its simplicity and revolutionary size (just over a foot tall) are intended to allow convenient use in patients' homes and give patients the freedom to travel with their therapy.   When combined with the NxStage Pureflow SL Dialysis Preparation System, patients are able to further simplify, using ordinary tap water to create dialysis fluid on demand.  Unlike conventional hemodialysis systems, the System One requires no special infrastructure to operate. Under the guidance of their physician, patients can use the NxStage System One, with their trained partners, where, how and when it best meets their needs, at home or on vacation.

About NxStage Medical

NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative systems for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. NxStage is leading the development of the home hemodialysis market in the US with the only portable hemodialysis machine, the System One, cleared for home use by the FDA. For more information on NxStage and its products, please visit the company's website at http://www.nxstage.com/.

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond NxStage's control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance or achievements including market acceptance and demand for NxStage's System One, growth in home hemodialysis, and certain other factors that may affect future operating results and which are detailed in NxStage's filings with the Securities and Exchange Commission, including Quarterly Report on Form 10Q for the quarter ended June 30, 2011.

In addition, the statements in this press release represent NxStage's expectations and beliefs as of the date of this press release. NxStage anticipates that subsequent events and developments may cause these expectations and beliefs to change. However, while NxStage may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, whether as a result of new information, future events, or otherwise. These forward-looking statements should not be relied upon as representing NxStage's expectations or beliefs as of any date subsequent to the date of this press release.

Contact:
Kristen K. Sheppard, Esq.
Investor Relations
ksheppard@nxstage.com


'/>"/>
SOURCE NxStage Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
2. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
3. Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
4. Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
5. Michigan Life Science and Innovation Center Opens in Former Pfizer Facility
6. Peregrine Pharmaceuticals Appoints Former Genentech Senior Executive Dr. Robert Garnick as Head of Regulatory Affairs
7. NGM Biopharmaceuticals Appoints Dr. Arthur D. Levinson, Former Genentech CEO, to its Board of Directors
8. Former Miss USA Shawnae Jebbia Shines with Siemens Pure
9. Secure eHealth, LLC Engages as a Consultant GSI Health Whose Principal and CEO is the Former Senior Advisor to National Coordinator for Health Information Technology
10. Former Air Force Surgeon General Joins Integrated Medical Systems Advisory Board
11. SCAI Statement on the Hospitalization of Former President Bill Clinton
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... The U.S. cannabis market is growing ... use in 2016. According to a new report published by ... estimated $7.2 billion in 2016 and is projected to grow ... recreational sales are projected to jump from $2.6 billion in ... The market may grow faster as the estimate was based ...
(Date:2/23/2017)... , Feb. 22, 2017 This report analyzes analyzes the ... report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... and forecasts are provided for the period 2015 through 2022. ... Market data and analytics are derived from primary and secondary ...
(Date:2/23/2017)... Ill. , Feb. 23, 2017 Takeda ... subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502) and Cognition ... PLC and Ctrl Group Limited, announced a collaboration to ... an Apple Watch wearable to monitor and assess cognitive ... Depression (MDD) is the leading cause of disability ...
Breaking Medicine Technology:
(Date:2/22/2017)... ... 22, 2017 , ... The National Academy of Certified Care ... April 2017 testing period. NACCM, a nonprofit organization, has provided the premier certification ... is periodically re-calibrated to ensure that newly certified professionals are prepared to work ...
(Date:2/22/2017)... ... February 22, 2017 , ... Giving patients with diabetes ... emergency room, fewer hospital admissions, and better blood pressure and glycemic control, a ... The study can be found here . , The study comes as ...
(Date:2/22/2017)... ... February 22, 2017 , ... In a 2012 survey, over ... not filling a prescription because they could not afford to pay for it. ... were 30-60%*. At the same time, hospitals, pharmacies, manufacturers and nursing ...
(Date:2/22/2017)... CA (PRWEB) , ... February 22, 2017 , ... Doctors ... recent addition of esteemed ophthalmologist, Dr. Steven H. Rauchman, practicing at North Valley ... in auto accidents, product liability, premise liability and other personal injury cases. These ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... newest advanced absorption cannabidiol (CBD) serum, “NANOCALM 300” Microemulsified Hemp Extract. This ... instant absorption from the mouth into the bloodstream. Far outpacing the ...
Breaking Medicine News(10 mins):